Molecular Epidemiology of Hormone-Metabolic Loci in Prostate Cancer
|
|
- Cory Skinner
- 5 years ago
- Views:
Transcription
1 Epiderryologic Reviews Copyright 2001 by the Johns Hopkins University Bloomberg School of Public Health All rights reserved Vol. 23, No. 1 Printed in U.S.A. Molecular Epidemiology of Hormone-Metabolic Loci in Prostate Cancer Nick M. Makridakis and Juergen K. V. Reichardt INTRODUCTION In the United States, some 180,400 men were diagnosed with prostate cancer in 2000 alone, and 31,900 men died of the disease during that same year (1). In fact, prostate cancer is the most commonly diagnosed malignancy among men in the United States (1). Prostate cancer is rare before the age of 30 years, but the rate of increase thereafter is such that by the time a man is 90 years old, he has almost a 100 percent chance of having the disease (2). There is a large variation in prostate cancer incidence rates between racial/ethnic groups in the United States, highest among African-Americans, intermediate among Caucasian-Americans and Hispanic-Americans, and lowest among Asian-Americans (3). These epidemiologic data provide support for a major genetic component to prostate cancer risk, although environmental risk factors could also be partially involved. In addition, epidemiologic and biochemical evidence suggests that variations on androgen levels may play a role in the risk for prostate cancer. For example, a few studies (albeit using mostly small sample sizes) indicate that adult dihydrotestosterone metabolite level variation among distinct racial/ethnic groups parallels their prostate cancer risk (e.g., Ross et al. (4)). ANDROGENS AND PROSTATE CANCER Androgens play an important role in normal and abnormal prostate development. Studies of androgens and prostate cancer go back nearly 60 years and were rewarded with a Nobel Prize (5, 6). Both testosterone and dihydrotestosterone have been shown to induce prostate adenocarcinomas in experimental rat models (7). Normal prostate growth and development are both induced by dihydrotestosterone. In men, testosterone is produced in large amounts by the testes (8). Testosterone is then irreversibly metabolized to dihydrotestosterone, mainly in the prostate gland. Dihydrotestosterone (or, much less efficiently, testosterone) Received for publication May 30, 2000, and accepted for publication February 7, Abbreviations: Cl, confidence interval; NADPH, nicotinamide adenine dinucleotide phosphate, reduced form; OR, odds ratio. From the Department of Biochemistry and Molecular Biology, Institute for Genetic Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA. Reprint requests to Dr. Juergen K. V. Reichardt, Institute for Genetic Medicine, University of Southern California, 2250 Alcazar Street, Los Angeles, CA ( reichard@hsc.usc.edu). is bound by the androgen receptor (figure 1). This complex then translocates to the cell nucleus where it activates transcription of several genes with androgen-responsive elements in their promoters (8). This process ultimately results in increased DNA synthesis (figure 1). Dihydrotestosterone is known to promote DNA synthesis and cell replication in the prostate (8). Thus, increased prostatic dihydrotestosterone levels may increase the chance for prostate cancer. The above data suggest that any one of the androgen metabolic loci may be a good candidate gene for prostate cancer predisposition. We chose to review epidemiologic data on four androgen metabolic loci, CYP17, SRD5A2, HSD3B2, and AR (figure 1) because they are the only androgen metabolic genes as of yet for which at least one study has demonstrated a positive association with prostate cancer predisposition. 17a-HYDROXYLASE/17,20 LYASE (CYP17) GENE Testosterone is synthesized from cholesterol in a series of enzymatic steps involving several of the cytochrome p450 enzymes (9). The enzyme 17a-hydroxylase/17,20 lyase (cytochrome p450cl7; EC ) catalyzes two sequential reactions in the biosynthesis of testosterone, in both the gonads and in the adrenals (figure 1). The first step is the conversion of pregnenolone to 17-hydroxypregnenolone (hydroxylase activity), and the second step is its subsequent conversion to C19 steroid dehydroepiandrosterone (lyase activity), a steroid with androgenic activity (9). The enzyme cytochrome p450cl7 is the product of the CYP17 gene (10) (figure 1). The CYP17 gene is located on chromosome 10 and is comprised of eight exons (11). A T to C nucleotide transition (*A2 allele) in the 5' untranslated region of the CYP17 gene creates a potential Spl binding site (CCACC box), 34 bp upstream from the initiation of translation but downstream from the transcription start site (11). Since it is thought that the number of Spl binding sites correlates with promoter activity (12), it is conceivable that this polymorphism results in increased transcription of the CYP17 gene. Kristensen et al. (13), however, showed that neither the CYP17*A2 nor the CYP17*A1 allele could form a complex with the Spl protein in electrophoretic mobility shift assays. Nevertheless, Lunn et al. (10) demonstrated that the CYP17*A2 allele occurred at a relatively higher frequency in Caucasian-American prostate cancer patients than in matched controls (odds ratio (OR) = 1.7; 95 percent confidence interval (CI): 1.0, 3.0). This finding supports the hypothesis that the CYP17*A2 allele may predispose men to 24
2 Molecular Epidemiology of Hormone-Metabolic Loci 25 HSD3B2 gene 3(3-Hydroxysteroid Dehydrogenase Preg DHEA -* 4-Dione 17a-Hydroxylase/ 17,20-Lyase t CYP17 gene 3f5-Hydroxysteroid Dehydrogenase, 3P-Diol 3a-Diol -* DHT 5oc-Reductase t Androgen AR SRD5A2 gene /" Receptor gene DHT/AR Complex 1 Transactivation i Cell Division FIGURE 1. Androgen metabolism leading to increased cell division in the prostate. Androgen metabolic genes analyzed in this review are presented in bold type. Steroid abbreviations: Preg, pregnenolone; DHEA, dehydroepiandrosterone; 4-Dione, 4-androstenedione; T, testosterone; DHT, dihydrotestosterone; 3a-Diol, 3a-androstanediol; 3B-Diol, 3B-androstanediol; AR, androgen receptor. develop prostate cancer through increased testosterone biosynthesis. Wadelius et al. (14), however, reported higher incidence of the CYP17*A1 allele in Swedish prostate cancer patients than in Swedish controls (OR = 1.6; 95 percent CI: 1.0, 2.5), and cited preliminary data that linked the *A1/*A1 CYP17 genotype to increased circulating androgen levels. This apparent contradiction can perhaps be explained by the existence of distinct prostate cancer predisposing CYP17 mutations that are in linkage disequilibrium with the *A1 allele in some racial/ethnic groups and the *A2 allele in other racial/ethnic groups. STEROID 5<x-REDUCTASETYPE II (SRD5A2) GENE Steroid 5a-reductase (testosterone 5oc-reductase; EC ) is a membrane-bound enzyme that catalyzes the irreversible conversion of testosterone to dihydrotestosterone (figure 1) with nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) as a cofactor (8). Two isozymes have been characterized so far in humans: the type I enzyme with an alkaline ph optimum, encoded by the SRD5A1 gene, and the type II enzyme with an acidic ph optimum in vitro, encoded by the SRD5A2 gene (15). Thigpen et al. (15) showed that the type I isozyme is expressed primarily in newborn scalp, skin, and liver, while the type II isozyme protein is expressed primarily in genital skin and the prostate gland. Cloning and characterization of the SRD5A2 gene has demonstrated that it is located on the short arm of human chromosome 2 (band 2p23) and that it is comprised of five exons and four introns (figure 2) (15). A rare disorder of male sexual differentiation, male pseudohermaphroditism due to 5a-reductase deficiency (originally called pseudovaginal ATG TAA (TA)n A49T V89L FIGURE 2. Schematic of the SRD5A2 locus encoding the prostatic or type II steroid 5<x-reductase. The translation start (ATG) and stop (TAA) codons are indicated above the gene, along with the (TA) n dinucleotide repeat polymorphism in the 3' untranslated region. Constitutional DNA missense substitutions are identified below the gene in the single-letter amino acid code. perineoscrotal hypospadias) (16), is caused by inactivating germline mutations in the SRD5A2 gene (17-19). Males affected with the 46 X, Y karyotype exhibit genital ambiguity and external female characteristics until puberty, at which point there is some development of male secondary sex characteristics, but the prostate remains highly underdeveloped (16). Thus, normal prostate development requires the normal function of the SRD5A2 gene. Many authors have reported a series of molecular investigations regarding the contribution of the SRD5A2 gene in prostate cancer risk (e.g., Reichart et al. (20), and Makridakis et al. (21, 22). The investigations began by examining a polymorphic (TA) n dinucleotide repeat marker in the 3' untranslated region of the SRD5A2 gene (figure 2) (20). This study revealed substantial allelic variation at this locus. Some of the polymorphic alleles were only found in
3 26 Makridakis and Reichardt African-American men (20) who are at the highest risk for prostate cancer in the world. Using mostly Caucasian- American samples, though, Kantoff et al. (23) showed no statistically significant difference in the distribution of this dinucleotide repeat marker among prostate cancer cases and controls. Subsequently, Makridakis et al. (21) reported the identification and characterization of an allelic variant that may decrease prostate cancer risk in Asian men: the V89L substitution, which replaces valine at codon 89 with leucine and reduces enzyme activity both in vitro and in vivo. Makridakis et al. (unpublished data) and others (10, 24), though, have found no statistically significant difference in the distribution of the V89L substitution between prostate cancer cases and controls. Finally, Makridakis et al. (22) reported data on a missense mutation, A49T (alanine-49 to threonine) (figure 2), that is associated with a 7.2-fold increased risk of advanced prostate cancer in African- American men (p = 0.001) and a 3.6-fold increased risk in Latino men (p = 0.04). This mutation also increases steroid 5cc-reductase activity fivefold in vitro (22). Jaffe et al. (25) subsequently showed a significant association between the presence of the A49T mutation and a greater frequency of extracapsular prostate cancer as well as a higher pathologic tumor-lymph node-metastasis stage and poor disease prognosis, in mostly Caucasian patients. In conclusion, out of all the SRD5A2 markers examined so far, only the A49T mutation has been associated with significantly increased prostate cancer predisposition. Interestingly, the SRD5A2 locus also encodes significant pharmacogenetic variation for different competitive steroid 5a-reductase inhibitors, such as finasteride (22, 26). For example, finasteride displays 11.7-fold lower affinity for the A49T mutant enzyme than for the wild-type protein in vitro (22). This pharmacogenetic variation should be taken into account when prescribing steroid 5oc-reductase inhibitors for the chemoprevention or treatment of prostatic diseases. In addition to prostate cancer predisposition, Akalu et al. (27) have also investigated the SRD5A2 gene for its possible contribution to tumor progression. They have reported common somatic genetic alterations in the SRD5A2 gene in prostate tumors at the polymorphic (TA) n dinucleotide repeat in its 3' untranslated region (27) (figure 2). Thus, the SRD5A2 gene may not only be involved in the predisposition to prostate cancer but also in its progression. 3/3-HYDROXYSTEROID DEHYDROGENASETYPE II (HSD3B2) GENE Dihydrotestosterone (as discussed above) is the most active androgen in the prostate gland (8). It is synthesized from testosterone by the enzyme steroid 5oc-reductase and is inactivated through a reductive reaction catalyzed by either 3-cc- or 3(3-hydroxysteroid dehydrogenase (figure 1) (8). Both reductions use nicotinamide adenine dinucleotide (phosphate), reduced form (NAD(P)H) as a cofactor (8). The product of either reaction, 3a- or 3(3-androstanediol, is excreted outside the prostate and circulates in the blood as glucuronide conjugate (11). Thus, the 3 p-hydroxy steroid dehydrogenase enzyme (EC ) is one of the two enzymes that initiate the irreversible inactivation of dihydrotestosterone in the prostate. In addition, 3p-hydroxysteroid dehydrogenase is responsible for the production of androstenedione in the adrenals, which in subsequent steps is converted to dihydrotestosterone in the prostate (figure 1). Thus, 3 (3-hydroxysteroid dehydrogenase may affect both the synthesis and degradation of dihydrotestosterone. Finally, it has been reported that the activity of the two 3-hydroxysteroid dehydrogenase enzymes is significantly lower in abnormal prostatic tissue (28). Thus, dihydrotestosterone might accumulate in the prostate because of slower degradation (figure 1). 3(3-hydroxysteroid dehydrogenase in humans can act on a number of steroid substrates, including dihydrotestosterone (29). This enzyme activity is encoded by two closely linked yet distinct loci: the HSD3B1 and HSD3B2 genes, which are both located in chromosome band Ipl3 (30). The type I gene (HSD3B1) encodes the isoform present in the placenta and peripheral tissues, such as skin and mammary gland, while expression of the type II enzyme is restricted to the adrenals and gonads (29, 31). Cloning and characterization of the human HSD3B2 gene has revealed that it spans about 7.8 kb of genomic DNA in four exons (figure 3) (32). Mutations in this gene cause male pseudohermaphroditism with congenital adrenal hyperplasia (31, 33, 34), but no mutations have yet been reported in prostate cancer patients. A complex dinucleotide repeat polymorphism has been reported in the third intron of the HSD3B2 gene (35). Verreault et al. (35) discovered nine alleles of a (TG) n (TA) n (CA) n short tandem repeat (figure 3). Devgan et al. (36) have subsequently identified substantial allelic differences, which include at least 25 different alleles, at the HSD3B2 locus among African-Americans, Asians, and Caucasians. Some of these alleles appear at higher frequencies in prostate cancer cases than in controls, in distinct racial/ethnic groups (36). This racial/ethnic diversity at the HSD3B2 locus suggests that it may play a role in the racial/ethnic variation in prostate cancer risk. Additional ATG (TG)n(TA)n(CA)n TGA FIGURE 3. Schematic representation of the HSD3B2 gene encoding the type II 3p-hydroxysteroid dehydrogenase enzyme. The translation start and stop codons are indicated above the gene. The complex (TG) n (TA) n (CA) n polymorphism in intron 3 is marked below the gene.
4 Molecular Epidemiology of Hormone-Metabolic Loci 27 screening of the HSD3B2 gene should be carried out for the identification of mutations that may predispose to prostate cancer, especially utilizing the high risk short tandem repeat alleles already characterized (36). ANDROGEN RECEPTOR (AFT) GENE Both testosterone and dihydrotestosterone exert their androgenic effects through the androgen receptor protein (figure 1), a transcription factor that transactivates many genes with androgen receptor elements in their promoters (8). The AR gene (figure 4) is located on the long arm of the X-chromosome, and its large exon 1 is responsible for the transactivation activity of its mature gene product (11). Increased activity or levels of the androgen receptor protein are expected to increase prostate cancer risk. The AR gene has been the focus of intense molecular epidemiologic investigations. It appears that a polymorphic (CAG) n trinucleotide repeat in the exon 1 of the AR gene (figure 4), which encodes a polyglutamine stretch, plays a role in predisposition to prostate cancer. Indeed, shorter alleles of the (CAG) n repeat seem to be associated with a modest (1.5- to 2.1-fold) increase in prostate cancer risk (37-39). Other studies, however, reported no association (40-42), or weak and statistically insignificant association (43), between the presence of shorter (CAG) n repeat alleles and prostate cancer. Shorter (CAG) n repeat alleles are related to an earlier age of prostate cancer diagnosis (42, 44). This polymorphic polyglutamine stretch also appears to have biochemical consequences in vitro. AR receptors with expanded (CAG) n repeats cloned from patients with Kennedy disease (an adultonset X-linked disease associated with low virilization, decreased sperm production, testicular atrophy, and reduced fertility) (11) exhibit 50 percent lower transactivation activity but normal androgen binding activity (11, 45). Thus, it is likely that shorter (CAG) n repeats are causing increased prostate cancer risk through increased androgen receptor transactivation (in accordance with the model in figure 1). Two additional AR gene polymorphisms, the (GGC) n trinucleotide repeat and the G1733 A (Stu I) single nucleotide polymorphism (figure 4), were evaluated for their role in prostate cancer predisposition. The Stu I polymorphism (Stu I alleles are designated *SJ and *S2, uncut and cut by the Stu I restriction endonuclease, respectively) was in linkage disequilibrium with both the (CAG) n and the (GGC) n trinucleotide repeat polymorphisms, but the two polymorphisms were equilibrated ATG (CAG)n G1733A (GGQn TGA }000000& FIGURE 4. Schematic representation of the AR gene encoding the androgen receptor transactivator. The translation start codon is indicated above the gene. The polymorphic markers in exon 1 of the gene are indicated below the gene. with respect to each other, in African-American controls (11). The *S1 Stu I allele was shown to be associated with a threefold higher prostate cancer risk among African-American men under the age of 65 years (11). This *S1 allele prostate cancerassociated risk did not seem to result from just shorter (CAG) n repeats as a function of linkage disequilibrium (11), yet its potential functional significance is unknown. On the other hand, the involvement of the (GGC) n AR gene repeat in prostate cancer predisposition has been controversial. Two studies have found no association (41, 46), another study demonstrated a modest increase in prostate cancer risk for short (less than 16) repeat alleles (43), while yet another study showed a modest increase in prostate cancer relapse risk for long (more than 16) (GGC) n repeat alleles (40). In conclusion, some of the genetic variants studied in the androgen receptor gene have been shown to cause increased predisposition to prostate cancer. Finally, somatic mutations in the AR gene, including AR gene amplification, have been shown to play a role during prostate tumor progression as well (e.g., reviewed by Barrack et al. (47); see also Tulley et al. (48), Culig et al. (49), and Visakorpi et al. (50)). OTHER GENES Another androgen metabolism gene that may play a role in prostate cancer predisposition is HSD17B3 encoding 17(3- hydroxysteroid dehydrogenase type III, the testicular 17- ketoreductase (51). This enzyme utilizes nicotinamide adenine dinucleotide phosphate, reduced form (NADP(H)) as a cofactor and favors the reduction of androstenedione to testosterone, over the reverse reaction (producing androstenedione), in the testis (51). Thus, mutations in this locus may increase the production of testosterone in the testis, which can directly or indirectly (through dihydrotestosterone) activate the androgen receptor, augmenting prostate cancer risk. The HSD17B3 gene is on chromosomal region 9q22 and contains 11 exons (51). No mutations of this gene have yet been reported in prostate cancer, but several inactivating HSD17B3 mutations have been reported to cause another form of male pseudohermaphroditism called 17(i-hydroxysteroid dehydrogenase deficiency (19, 51, 52). Estrogens are also suspected to contribute to the etiology of prostate cancer and benign prostatic hypertrophy (e.g., Bosland (6), Tsugaya et al. (53), Bonkhoff et al. (54)). Aromatase cytochrome p450, the product of the CYP19 gene, is mainly localized in the ovary and the placenta, and it converts androgen to estrogen (55). Aromatase mrna and protein have both been detected in benign prostatic hypertrophy and prostate cancer tissue, but not at significantly different levels between cancerous and noncancerous tissue (53, 56). Several CYP19 polymorphisms have been investigated in breast cancer (e.g., Probst-Hensch et al. (57), Kristensen et al. (58)), but none in prostate cancer. With respect to the estrogen receptor genes, the classic estrogen receptor (ERoc), but not ERP, has been shown to be expressed in prostate cancer and premalignant prostatic lesions (e.g., Bonkhoff et al. (54)), yet again no ERoc polymorphisms have been investigated in prostate cancer.
5 28 Makridakis and Reichardt CONCLUSIONS Despite the ample evidence linking androgens and prostate cancer, convincing molecular epidemiologic evidence for the involvement of androgen metabolic loci in prostate cancer exists for only one single point mutation so far, the A49T mutation in the SRD5A2 gene. Two independent studies confirm a significant association between the presence of the A49T mutation and the presence of advanced prostate cancer in three racial/ethnic groups. Mechanistic/biochemical evidence also exists that provides a plausible etiology for this increased prostate cancer risk: enhanced dihydrotestosterone production of the mutant allele (see model in figure 1). Other polymorphisms, though, yielded mixed results. The (CAG) n repeat in the AR gene, for example, has been shown by several studies both to be associated with, and not to be associated with, prostate cancer in Caucasians, even though mechanistic/biochemical data supportive of an etiologic association exists. The A] polymorphism of the CYP17 gene yielded conflicting results in two epidemiologic studies. Some of the epidemiologic studies reviewed here are plagued by various problems in their experimental design: small sample size, absent or inadequate stratification by age between cases and controls, and inclusion of cases diagnosed before and after the availability of prostate-specific antigen testing, in the same study set. The latter study design creates variability of disease diagnosis and can be circumvented by stratification by year at diagnosis. However, even discounting all of those problematic studies does not lead to a clear understanding of the role of, for example, the (CAG) n androgen receptor repeat in prostate cancer predisposition. Any epidemiologic study can suffer from publication bias; null studies are much less likely to be submitted for publication. Yet, prostate cancer epidemiologists face additional obstacles that may explain most of the observed discrepancies. First, prostate cancer is very common. At autopsy, 64 percent of men aged years are shown to have prostatic adenocarcinoma (59). This fact increases the probability that many of the study controls may actually be undiagnosed cases. This, in turn, will reduce the "observed" relative risk for any polymorphism studied, yet it would mostly impact polymorphisms with low penetrance (low "actual" relative risk) to the point that some studies find a weak positive association while other studies find no association at all. Second, it is now recognized that prostate cancer involves more loci than other common cancers, such as breast cancer (60). This enhanced genetic heterogeneity can effectively reduce the contribution of each particular genetic modifier so that, for example, larger sample sizes or very homogeneous (inbred) populations may be required to positively identify individual genes. It also makes it more likely that distinct genes would cause disease in each racial/ethnic group, rendering comparisons between, for example, US and European Caucasians less conclusive. Finally, prostate cancer epidemiologists studying androgen metabolic genes should not discount the effects of environmental modifiers that may be metabolized by some of the androgen metabolic enzymes. Diet, and in particular animal fat intake (which contains cholesterol and steroids), may differ significantly among distinct study populations, and, thus, may account for some of the observed discrepancies (11). ACKNOWLEDGMENTS This work was supported by grant nos. CA68581 and CA83112 from the National Cancer Institute, grant no. 99- OO53V from the California Cancer Research Program, and from the T. J. Martell Foundation to one of the authors (J.K.V.R.). REFERENCES 1. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, CA Cancer J Clin 2000;50: Peehl DM. Vitamin D and prostate cancer risk. Eur Urol 1999;35:392^. 3. Bernstein L, Ross RK. Cancer in Los Angeles County: a portrait of incidence and mortality. Los Angeles, CA: University of Southern California Press, Ross RK, Bernstein L, Lobo RA, et al. 5a-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992;339: Huggins C, Hodges CV. Studies on prostate cancer. Cancer Res 1941,1: Bosland MC. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 2000;(27): Noble RL. The development of prostate adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977;37: Cheng E, Lee C, Grayhack J. Endocrinology of the prostate. In: Lepor H, Lawson RK, eds. Prostate diseases. Philadelphia, PA: Saunders, 1993: Waterman MR, Keeney DS. Genes involved in androgen biosynthesis and the male phenotype. Horm Res 1992;38: Lunn RM, Bell DA, Mohler JL, et al. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999;20: Ross RK, Pike MC, Coetzee GA, et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 1998;58: Kadonaga JT, Jones KA, Tjian R. Promoter specific activation of RNA polymerase II transcription by Spl. Trends BiochemSci 1986; 11: Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, et al. CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1. Cancer Res 1999;59: Wadelius M, Andersson AO, Johansson JE, et al. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999;9: Thigpen AE, Silver RI, Guileyardo JM, et al. Tissue distribution and ontogeny of steroid 5a-reductase isozyme expression. J Clin Invest 1993;92: Wilson JD, Griffin JE, Russell DW. Steroid 5a-reductase 2 deficiency. Endocr Rev 1993;14: Thigpen AE, Davis DL, Milatovich A, et al. Molecular genetics of steroid 5<x-reductase 2 deficiency. J Clin Invest 1992;90: Russell DW, Wilson JD. Steroid 5a-reductase: two genes/two enzymes. Annu Rev Biochem 1994;63: Can S, Zhu YS, Cai LQ, et al. The identification of 5areductase-2 and 17P-hydroxysteroid dehydrogenase-3 gene defects in male pseudohermaphrodites from a Turkish kindred. J Clin Endocrinol Metab 1998;83: Reichardt JKV, Makridakis N, Henderson BE, et al. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res 1995 ;55: Makridakis N, Ross RK, Pike MC, et al. A prevalent
6 Molecular Epidemiology of Hormone-Metabolic Loci 29 missence substitution that modulates activity of prostatic steroid 5oc-reductase. Cancer Res 1997,57: Makridakis NM, Ross RK, Pike MC, et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999,354: Kantoff PW, Febbo PG, Giovannucci E, et al. A polymorphism of the 5oc-reductase gene and its association with prostate cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev 1997;6: Febbo PG, Kantoff PW, Platz EA, et al. The V89L polymorphism in the 5a-reductase type 2 gene and risk of prostate cancer. Cancer Res 1999;59: Jaffe JM, Malkowicz SB, Walker AH, et al. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res 2000;60: Makridakis NM, di Salle E, Reichardt JKV. Biochemical and pharmacogenetic dissection of human steroid 5a-reductase type II. Pharmacogenetics 2000; 10: Akalu A, Dlmajian DE, Highshaw RA, et al. Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5areductase during prostate cancer progression. J Urol 1999; 161: Bartsch W, Klein H, Schiemann U, et al. Enzymes of androgen formation and degradation in the human prostate. Ann N Y Acad Sci 1990;595: Labrie F, Simard J, Luu-The V, et al. Structure and tissuespecific expression of 3 (i-hydroxysteroid dehydrogenase/ 5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissue. J Steroid Biochem Mol Biol 1992;41: Berube D, Luu-The V, Lachance Y, et al. Assignment of the human 3(3-hydroxysteroid dehydrogenase gene (HSDB3) to the pl3 band of chromosome 1. Cytogenet Cell Genet 1989; 52: Rheaume E, Simard J, Morel Y, et al. Congenital adrenal hyperplasia due to point mutations in the type II 3(3-hydroxysteroid dehydrogenase gene. Nat Genet 1992; 1: Lachance Y, Luu-The V, Verreault H, et al. Structure of the human type II 3 P-hydroxy steroid dehydrogenase/delta 5 / delta" isomerase (3J5-HSD) gene: adrenal and gonadal specificity. DNACell Biol 1991;10:701-ll. 33. Simard J, Rheaume E, Sanchez R, et al. Molecular basis of congenital adrenal hyperplasia due to 3P-hydroxysteroid dehydrogenase deficiency. Mol Endocrinol 1993;7: Sanchez R, Mebarki F, Rheaume E, et al. Functional characterization of the novel L108W and P186L mutations detected in the type II 3P-hydroxysteroid dehydrogenase gene of a male pseudohermaphrodite with congenital adrenal hyperplasia. Hum Mol Genet 1994;3:1639^ Verreault H, Dufort I, Simard J, et al. Dinucleotide repeat polymorphisms in the HSD3B2 gene. Hum Mol Genet 1994;3: Devgan SA, Henderson BE, Yu MC, et al. Genetic variation of 3P-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Prostate 1997;33: Giovannucci E, Stampfer MJ, Krithivas K, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 1997,94: Ingles S A, Ross RK, Yu MA, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89: Xue W, Irvine RA, Yu MC, et al. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res 2000;60: Edwards SM, Badzioch MD, Minter R, et al. Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival, hit J Cancer 1999,84: Correa-Cerro L, Wohr G, Haussler J, et al. (CAG) n CAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. Eur J Hum Genet 1999;7: Bratt O, Borg A, Kristoffersson U, et al. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 1999;81: Stanford JL, Just JJ, Gibbs M, et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997;57: Hardy DO, Scher HI, Bogenreider T, et al. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab 1996;81: Tut TG, Ghadessy FJ, Trifiro MA, et al. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab 1997;82: Platz EA, Giovannucci E, Dahl DM, et al. The androgen receptor gene GGN microsatellite and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7: Barrack ER. Androgen receptor mutations in prostate cancer. Mt Sinai J Med 1996;63: Tilley WD, Buchannan G, Hickey TE, et al. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996;2: Culig Z, Hobisch A, Hittmair A, et al. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 1998,35: Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9: Geissler WM, Davis DL, Wu L, et al. Male pseudohermaphroditism caused by mutations of testicular 17P-hydroxysteroid dehydrogenase 3. Nat Genet 1994;7: Andersson S, Geissler WM, Wu L, et al. Molecular genetics and pathophysiology of 17P-hydroxysteroid dehydrogenase 3 deficiency. J Clin Endocrinol Metab 1996;81: Tsugaya M, Harada N, Tozawa K, et al. Aromatase mrna levels in benign prostatic hyperplasia and prostate cancer. Int J Urol 1996,3: Bonkhoff H, Fixemer T, Hunsicker I, et al. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol 1999;155: Harada N, Utsumi T, Takagi Y. Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc Natl Acad Sci USA 1993;90: Hiramatsu M, Maehara I, Ozaki M, et al. Aromatase in hyperplasia and carcinoma of the human prostate. Prostate 1997,31: Probst-Hensch NM, Ingles SA, Diep AT, et al. Aromatase and breast cancer susceptibility. Endocr Relat Cancer 1999;6: Kristensen VN, Harada N, Yoshimura N, et al. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 2000; 19: Sakr WA, Grignon DJ, Grissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439^ Ostrander EA, Stanford JL. Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet 2000;67:
GEN GEN: THE GENOMIC GENETIC ANALYSIS OF ANDROGEN-METABOLIC GENES AND PROSTATE CANCER AS A PARADIGM FOR THE DISSECTION OF COMPLEX PHENOTYPES
[Frontiers in Bioscience, 4, d596-600, July 15, 1999] GEN GEN: THE GENOMIC GENETIC ANALYSIS OF ANDROGEN-METABOLIC GENES AND PROSTATE CANCER AS A PARADIGM FOR THE DISSECTION OF COMPLEX PHENOTYPES Juergen
More informationSerum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk
Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk H Kakinuma 1, N Tsuchiya 1, T Habuchi 1 *, C Ohyama 1, S Matsuura 1, L Wang 1, A Nakamura 2
More informationChapter 2: The Role of Steroid Hormones in Prostate Carcinogenesis
Chapter 2: The Role of Steroid Hormones in Prostate Carcinogenesis Maarten C. Bosland Carcinoma of the prostate is the most frequently diagnosed malignancy and the second leading cause of death as a result
More informationWhen testes make no testosterone: Identifying a rare cause of 46, XY female phenotype in adulthood
When testes make no testosterone: Identifying a rare cause of 46, XY female phenotype in adulthood Gardner DG, Shoback D. Greenspan's Basic & Clinical Endocrinology, 10e; 2017 Sira Korpaisarn, MD Endocrinology
More informationEvidence for an association between the SRD5A2 (type II steroid 5α-reductase) locus and prostate cancer in Italian patients
147 Evidence for an association between the SRD5A2 (type II steroid 5α-reductase) locus and prostate cancer in Italian patients K. Margiotti a,b, F. Sangiuolo a, A. De Luca a, F. Froio c, C.L. Pearce d,
More informationLinkage analysis: Prostate Cancer
Linkage analysis: Prostate Cancer Prostate Cancer It is the most frequent cancer (after nonmelanoma skin cancer) In 2005, more than 232.000 new cases were diagnosed in USA and more than 30.000 will die
More informationSCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY
1 SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL SEMINAR: SEX HORMONES PART 1 An Overview What are steroid hormones? Steroid
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Congenital Adrenal Hyperplasia in Saudi Arabia: The Biochemical Characteristics Nasir A. M.
More informationHormones and Prostate Cancer: What's Next?
Epidemiologic Reviews Copyright 2001 by the Johns Hopkins University Bloomberg School of Public Health All rights reserved Vol. 23, No. 1 Printed in U.S.A. Hormones and Prostate Cancer: What's Next? Ann
More informationTopic No. & Title: Topic 4 Biosynthesis and secretion of adrenal, ovarian and testicular hormones-factors influencing secretion
[Academic Script] Biosynthesis and secretion of adrenal, ovarian and testicular hormones-factors influencing secretion Subject: Zoology Course: B.Sc. 2 nd Year Paper No. & Title: Z-203B Vertebrate Endocrinology
More informationSEX STERIOD HORMONES I: An Overview. University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences PBL MBBS III VJ Temple
SEX STERIOD HORMONES I: An Overview University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences PBL MBBS III VJ Temple 1 What are the Steroid hormones? Hormones synthesized
More informationIN SUMMARY HST 071 NORMAL & ABNORMAL SEXUAL DIFFERENTIATION Fetal Sex Differentiation Postnatal Diagnosis and Management of Intersex Abnormalities
Harvard-MIT Division of Health Sciences and Technology HST.071: Human Reproductive Biology Course Director: Professor Henry Klapholz IN SUMMARY HST 071 Title: Fetal Sex Differentiation Postnatal Diagnosis
More informationSynthesis of sex steroids
Synthesis of sex steroids CH 3 NAD(P)H NAD(P)+ Dehidroepiandroszteron Androszténdion 17- -hidroxiszteroid dehidrogenáz CH 3 dehydroepiandrosterone Dehidroepiandroszteron (DHEA) 3SDH Koleszterin CH 3 aromatase
More informationDEFINITION: Masculinization of external genitalia in patients with normal 46XX karyotype.
INTERSEX DISORDERS DEFINITION: Masculinization of external genitalia in patients with normal 46XX karyotype. - Degree of masculinization variable: - mild clitoromegaly - complete fusion of labia folds
More informationSesh Kamal Sunkara Aberdeen Fertility Centre Aberdeen Maternity Hospital University of Aberdeen Aberdeen, UK
Sesh Kamal Sunkara Aberdeen Fertility Centre Aberdeen Maternity Hospital University of Aberdeen Aberdeen, UK Declared no potential conflict of interest Genetic aetiology of poor and hyper responders Sesh
More informationBIOSYNTHESIS OF STEROID HORMONES
BIOSYNTHESIS OF STEROID HORMONES Sri Widia A Jusman Department of Biochemistry & Molecular Biology FMUI sw/steroidrepro/inter/08 1 STEROID HORMONES Progestins (21 C) Glucocorticoids (21 C) Mineralocorticoids
More informationChemical Classification of Hormones
Steroid Hormones Chemical Classification of Hormones Hormones are chemical messengers that transport signals from one cell to another There are 4 major chemical classes of hormones steroid hormones - i.e.
More informationCYP21A2 Mutations Found in Congenital Adrenal Hyperplasia Patients in the California Population
CYP21A2 Mutations Found in Congenital Adrenal Hyperplasia Patients in the California Population Christopher N. Greene, Ph.D. Newborn Screening and Molecular Biology Branch National Center for Environmental
More informationCase Based Urology Learning Program
Case Based Urology Learning Program Resident s Corner: UROLOGY Case Number 3 CBULP 2011 019 Case Based Urology Learning Program Editor: Associate Editors: Manager: Case Contributors: Steven C. Campbell,
More informationX/04/$20.00/0 Endocrine Reviews 25(6): Copyright 2004 by The Endocrine Society doi: /er
0163-769X/04/$20.00/0 Endocrine Reviews 25(6):947 970 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/er.2003-0030 Overview of Steroidogenic Enzymes in the Pathway from Cholesterol
More informationCYP19 gene polymorphisms and the susceptibility to breast cancer in Xinjiang Uigur women
CYP19 gene polymorphisms and the susceptibility to breast cancer in Xinjiang Uigur women L. Yang, X.Y. Wang, Y.T. Li, H.L. Wang, T. Wu, B. Wang, Q. Zhao, D. Jinsihan and L.P. Zhu The Department of Mammary
More informationMedical management of Intersex disorders. Dr. Abdulmoein Al-Agha, Ass. Professor & Consultant Pediatric Endocrinologist KAAUH, Jeddah
Medical management of Intersex disorders Dr. Abdulmoein Al-Agha, Ass. Professor & Consultant Pediatric Endocrinologist KAAUH, Jeddah Is it a boy or a girl? The birth of an intersex infant is often viewed
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More informationComprehensivePLUS Hormone Profile with hgh
OLEBound400: 801 SW 16th St Suite 126 Renton WA 98057 425.271.8689 425.271.8674 (Fax) ComprehensivePLUS Hormone Profile with hgh Doctor ID Patient Name 6206 Doe, Jane Age Sex Date of Birth 44 F Date Collected
More informationCrosstalk between Adiponectin and IGF-IR in breast cancer. Prof. Young Jin Suh Department of Surgery The Catholic University of Korea
Crosstalk between Adiponectin and IGF-IR in breast cancer Prof. Young Jin Suh Department of Surgery The Catholic University of Korea Obesity Chronic, multifactorial disorder Hypertrophy and hyperplasia
More informationDEVELOPMENT (DSD) 1 4 DISORDERS OF SEX
Wit JM, Ranke MB, Kelnar CJH (eds): ESPE classification of paediatric endocrine diagnosis. 4. Disorders of sex development (DSD). Horm Res 2007;68(suppl 2):21 24 ESPE Code Diagnosis OMIM ICD 10 4 DISORDERS
More informationAssociations between the SRD5A2 gene V89L and TA repeat polymorphisms and breast cancer risk: a meta-analysis
Associations between the SRD5A2 gene V89L and TA repeat polymorphisms and breast cancer risk: a meta-analysis D. Zhang 1, Q. Li 2, H.-C. Qu 3, T. Yu 2 and Y.-R. Liu 1 1 College of Basic Medical Science,
More informationAndrogens and prostate cancer: insights from abiraterone acetate and other novel agents
Androgens and prostate cancer: insights from abiraterone acetate and other novel agents Ian Davis Ludwig Institute for Cancer Research Austin Health, Melbourne, Australia Supported in part by an Australian
More informationSex Determination and Gonadal Sex Differentiation in Fish
Sex Determination and Gonadal Sex Differentiation in Fish Yoshitaka Nagahama Okazaki National Research Institutes, Japan This first slide shows the processes of gonadal sex differentiation and gametogenesis
More informationGenetics and Genomics in Medicine Chapter 8 Questions
Genetics and Genomics in Medicine Chapter 8 Questions Linkage Analysis Question Question 8.1 Affected members of the pedigree above have an autosomal dominant disorder, and cytogenetic analyses using conventional
More informationLESSON 3.2 WORKBOOK. How do normal cells become cancer cells? Workbook Lesson 3.2
For a complete list of defined terms, see the Glossary. Transformation the process by which a cell acquires characteristics of a tumor cell. LESSON 3.2 WORKBOOK How do normal cells become cancer cells?
More informationPHYSIOLOGY AND PATHOLOGY OF SEXUAL DIFFERENTIATION
PHYSIOLOGY AND PATHOLOGY OF SEXUAL DIFFERENTIATION Prof. Dr med. Jolanta Słowikowska-Hilczer Department of Andrology and Reproductive Endocrinology Medical University of Łódź, Poland Sexual determination
More informationPlease Take Seats by Gender as Shown Leave Three Seats Empty in the Middle
Please Take Seats by Gender as Shown Leave Three Seats Empty in the Middle Women Men Sexual Differentiation & Development Neal G. Simon, Ph.D. Professor Dept. of Biological Sciences Signaling Cascade &
More informationSex Determination and Development of Reproductive Organs
Sex Determination and Development of Reproductive Organs Sex determination The SRY + gene is necessary and probably sufficient for testis development The earliest sexual difference appears in the gonad
More informationCorrelations between the COMT gene rs4680 polymorphism and susceptibility to ovarian cancer
Correlations between the COMT gene rs4680 polymorphism and susceptibility to ovarian cancer W. Pan 1 and H. Liao 2 1 Department of Obstetrics and Gynecology, Huangshi Central Hospital of Hubei Province
More informationThe Induction of Prostatic Hypertrophy in the Dog with Androstanediol
The Induction of Prostatic Hypertrophy in the Dog with Androstanediol PATRICK C. WALSH and JEAN D. WILSON From the Department of Internal Medicine, The University of Texas Southwestern Medical School,
More informationSex chromosomes and sex determination
Sex chromosomes and sex determination History (1) 1940-ties Alfred Jost embryo-surgical experiments on gonads gonadal sex; male gonadal sex presence of testes; female gonadal sex lack of testes. History
More informationThe Biology and Genetics of Cells and Organisms The Biology of Cancer
The Biology and Genetics of Cells and Organisms The Biology of Cancer Mendel and Genetics How many distinct genes are present in the genomes of mammals? - 21,000 for human. - Genetic information is carried
More informationSALSA MLPA probemix P185-C2 Intersex Lot C2-1015: As compared to the previous version C1 (lot C1-0611), the lengths of four probes have been adjusted.
mix P185-C2 Intersex Lot C2-1015: As compared to the previous version C1 (lot C1-0611), the lengths of four s have been adjusted. The sex-determining region on chromosome Y (SRY) is the most important
More informationBiology of Reproduction- Zool 346 Exam 2
Biology of Reproduction- Zool 346 Exam 2 ANSWER ALL THE QUESTIONS ON THE ANSWER SHEET. THE ANSWER ON THE ANSWER SHEET IS YOUR OFFICIAL ANSWER. Some critical words are boldfaced. This exam is 7 pages long.
More informationConditions. Name : dummy Age/sex : xx Y /x. Lab No : xxxxxxxxx. Rep Centre : xxxxxxxxxxx Ref by : Dr. xxxxxxxxxx
Name : dummy Age/sex : xx Y /x Lab No : xxxxxxxxx Rep Centre : xxxxxxxxxxx Ref by : Dr. xxxxxxxxxx Rec. Date : xx/xx/xx Rep Date : xx/xx/xx GENETIC MAPPING FOR ONCOLOGY Conditions Melanoma Prostate Cancer
More informationDominic J Smiraglia, PhD Department of Cancer Genetics. DNA methylation in prostate cancer
Dominic J Smiraglia, PhD Department of Cancer Genetics DNA methylation in prostate cancer Overarching theme Epigenetic regulation allows the genome to be responsive to the environment Sets the tone for
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AD Award Number: DAMD17-01-1-0112 TITLE: Genetic Epidemiology of Prostate Cancer PRINCIPAL INVESTIGATOR: Susan L. Neuhausen, Ph.D. CONTRACTING ORGANIZATION: University of California, Irvine Irvine, California
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationIts Role in Development of Prostate Cancer and Potential Risk From Use as Hormone Replacement Therapy
LEADING ARTICLE Drugs & Aging 2000 Dec; 17 (6): 431-439 1170-229X/00/0012-0431/$20.00/0 Adis International Limited. All rights reserved. Testosterone Its Role in Development of Prostate Cancer and Potential
More informationCourse Title Form Hours subject
Course Title Form Hours subject Types, and structure of chromosomes L 1 Histology Karyotyping and staining of human chromosomes L 2 Histology Chromosomal anomalies L 2 Histology Sex chromosomes L 1 Histology
More informationChapter 18 Development. Sexual Differentiation
Chapter 18 Development Sexual Differentiation There Are Many Levels of Sex Determination Chromosomal Sex Gonadal Sex Internal Sex Organs External Sex Organs Brain Sex Gender Identity Gender Preference
More information1) DNA unzips - hydrogen bonds between base pairs are broken by special enzymes.
Biology 12 Cell Cycle To divide, a cell must complete several important tasks: it must grow, during which it performs protein synthesis (G1 phase) replicate its genetic material /DNA (S phase), and physically
More informationReview Article Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes
Am J Cancer Res 2013;3(2):127-151 www.ajcr.us /ISSN:2156-6976/ajcr0000181 Review Article Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes Jie Li 1,2,
More informationGONADAL FUNCTION: An Overview
GONADAL FUNCTION: An Overview University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences Clinical Biochemistry BMLS III & BDS IV VJ Temple 1 What are the Steroid hormones?
More informationBiochemistry of Cancer and Tumor Markers
Biochemistry of Cancer and Tumor Markers The term cancer applies to a group of diseases in which cells grow abnormally and form a malignant tumor. It is a long term multistage genetic process. The first
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: Cambridge RGC Approved: September 2012
More informationMultistep nature of cancer development. Cancer genes
Multistep nature of cancer development Phenotypic progression loss of control over cell growth/death (neoplasm) invasiveness (carcinoma) distal spread (metastatic tumor) Genetic progression multiple genetic
More informationGenetics and Pharmacogenetics in Human Complex Disorders (Example of Bipolar Disorder)
Genetics and Pharmacogenetics in Human Complex Disorders (Example of Bipolar Disorder) September 14, 2012 Chun Xu M.D, M.Sc, Ph.D. Assistant professor Texas Tech University Health Sciences Center Paul
More informationChapter 11 Gene Expression
Chapter 11 Gene Expression 11-1 Control of Gene Expression Gene Expression- the activation of a gene to form a protein -a gene is on or expressed when it is transcribed. -cells do not always need to produce
More informationUniversity of Southern California Los Angeles, California Approved for Public Release; Distribution Unlimited
it AD Award Number: DAMD17-00-1-0102 TITLE: Molecular Determinants of Prostate Cancer Progression Across Race-Ethnicity PRINCIPAL INVESTIGATOR: Ronald K. Ross, M.D. CONTRACTING ORGANIZATION: University
More informationRelationship between CYP17 gene polymorphisms and risk of prostate cancer
Relationship between CYP17 gene polymorphisms and risk of prostate cancer J. Song, Z.-H. Tao, X.-Y. Liu, S. Gong and L. Gan Centre for Preclinical Medicine, SiChuan Medical University, Luzhou, Sichuan,
More informationIntracrine Androgens Enhance Decidualization and Modulate Expression of Human
Intracrine Androgens Enhance Decidualization and Modulate Expression of Human Endometrial Receptivity Genes. Authors: Douglas A Gibson 1, Ioannis Simitsidellis 1, Fiona L Cousins 1*, Hilary O.D. Critchley
More informationCYP17 Gene Polymorphism and its Association in North Indian Prostate Cancer Patients
CYP17 Gene Polymorphism and its Association in North Indian Prostate Cancer Patients RANBIR CHANDER SOBTI 1, LIPSY GUPTA 1, HITENDER THAKUR 1, AMLESH SETH 2, SHARWAN K. SINGH 3 and PUSHPINDER KAUR 1 1
More informationUterine Fibroids: No financial disclosures. Current Challenges, Promising Future. Off-label uses of drugs. Alison Jacoby, MD.
Uterine Fibroids: Current Challenges, Promising Future Alison Jacoby, MD Professor, Dept of Obstetrics, Gynecology and Reproductive Sciences No financial disclosures Off-label uses of drugs The BIG Questions
More informationChapter 16: Steroid Hormones (Lecture 17)
Chapter 16: Steroid Hormones (Lecture 17) A) 21 or fewer carbon atoms B) Precursor: 27 carbon cholesterol C) major classes of steroid hormones 1) progestagens a) progesterone- prepares lining of uterus
More informationSAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN:
Patient: Age: 40 Sex: F MRN: SAMPLE PATIENT Order Number: Completed: Received: Collected: SAMPLE REPORT Progesterone ng/ml 0.34 0.95 21.00 DHEA-S mcg/dl Testosterone ng/ml 48 35 0.10 0.54 0.80 430 Sex
More informationREVIEwS. Estrogen and androgen signaling in the pathogenesis of BPH. Clement K. M. Ho and Fouad K. Habib
REVIEwS Estrogen and androgen signaling in the pathogenesis of BPH Clement K. M. Ho and Fouad K. Habib Abstract Estrogens and androgens have both been implicated as causes of benign prostatic hyperplasia
More informationDOES THE BRCAX GENE EXIST? FUTURE OUTLOOK
CHAPTER 6 DOES THE BRCAX GENE EXIST? FUTURE OUTLOOK Genetic research aimed at the identification of new breast cancer susceptibility genes is at an interesting crossroad. On the one hand, the existence
More informationIntroduction to Cancer Biology
Introduction to Cancer Biology Robin Hesketh Multiple choice questions (choose the one correct answer from the five choices) Which ONE of the following is a tumour suppressor? a. AKT b. APC c. BCL2 d.
More informationReproductive. Estrone sulfate Analyte Information
Reproductive Estrone sulfate Analyte Information - 1 - Estrone sulfate Introduction Estrone sulfate (E1-S) is a sulfate derivative of estrone, and is the most abundant form of circulating estrogens in
More informationCancer. October is National Breast Cancer Awareness Month
Cancer October is National Breast Cancer Awareness Month Objectives 1: Gene regulation Explain how cells in all the different parts of your body develop such different characteristics and functions. Contrast
More informationAction of reproductive hormones through the life span 9/22/99
Action of reproductive hormones through the life span Do reproductive hormones affect the life span? One hypothesis about the rate of aging asserts that there is selective pressure for either high rate
More informationSALSA MLPA KIT P050-B2 CAH
SALSA MLPA KIT P050-B2 CAH Lot 0510, 0909, 0408: Compared to lot 0107, extra control fragments have been added at 88, 96, 100 and 105 nt. The 274 nt probe gives a higher signal in lot 0510 compared to
More informationTumor suppressor genes D R. S H O S S E I N I - A S L
Tumor suppressor genes 1 D R. S H O S S E I N I - A S L What is a Tumor Suppressor Gene? 2 A tumor suppressor gene is a type of cancer gene that is created by loss-of function mutations. In contrast to
More informationHuman inherited diseases
Human inherited diseases A genetic disorder that is caused by abnormality in an individual's DNA. Abnormalities can range from small mutation in a single gene to the addition or subtraction of a whole
More informationUCL. Gerard Conway. Treatment of AIS patients in multidisciplinary teams in UK. Tratamiento del SIA en equipos multidisciplinares en el Reino Unido
UCL Treatment of AIS patients in multidisciplinary teams in UK Tratamiento del SIA en equipos multidisciplinares en el Reino Unido Gerard Conway London, UK University College London Hospitals University
More informationSelection Bias in the Assessment of Gene-Environment Interaction in Case-Control Studies
American Journal of Epidemiology Copyright 2003 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 158, No. 3 Printed in U.S.A. DOI: 10.1093/aje/kwg147 Selection Bias in the
More informationPHARMACOGENETICS OF BREAST CANCER
PHARMACOGENETICS OF BREAST CANCER MALGORZATA JAREMKO, PhD Mount Sinai School of Medicine, Department of Genetics and Genomic Sciences Outlines Breast cancer therapeutic situation Pharmacogenetics of antiestrogen
More informationAward Number: W81XWH TITLE: CYP1B1 Polymorphism as a Risk Factor for Race-Related Prostate Cancer
AD Award Number: W81XWH-04-1-0579 TITLE: CYP1B1 Polymorphism as a Risk Factor for Race-Related Prostate Cancer PRINCIPAL INVESTIGATOR: Yuichiro Tanaka, Ph.D. Rajvir Dahiya, Ph.D. CONTRACTING ORGANIZATION:
More informationAccess to the published version may require journal subscription. Published with permission from: Elsevier
This is an author produced version of a paper published in European Urology. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination. Citation
More informationJoint AEPCOS/Endocrine Society Update Meeting in ENDO 2017
Joint AEPCOS/Endocrine Society Update Meeting in Orlando @ ENDO 2017 GUT, MICROBIOME AND FAT: ORIGINS OF PCOS METABOLIC DISEASE? ORANGE COUNTY CONVENTION CENTER, ORLANDO, FL, USA, MARCH 31, 2017 CALL FOR
More informationMelatonin and its Role in the Inhibition of Breast Cancer Ciara Nicol Ross Copyright 2014 by Ciara Ross and Koni Stone
1 Melatonin and its Role in the Inhibition of Breast Cancer Ciara Nicol Ross Copyright 2014 by Ciara Ross and Koni Stone Cancer is a disease caused by out of control division of abnormal cells within a
More informationUNIVERSITY OF CALIFORNIA, LOS ANGELES
UNIVERSITY OF CALIFORNIA, LOS ANGELES BERKELEY DAVIS IRVINE LOS ANGELES MERCED RIVERSIDE SAN DIEGO SAN FRANCISCO UCLA SANTA BARBARA SANTA CRUZ DEPARTMENT OF EPIDEMIOLOGY SCHOOL OF PUBLIC HEALTH CAMPUS
More informationHormonal effects of prohormones in bovines
Hormonal effects of prohormones in bovines Jeroen Rijk Supervisors: Michel Nielen, Maria Groot and Ad Peijnenburg RIKILT Institute of Food Safety, Wageningen UR WT Theme 3 Introduction Prohormone = A chemical
More informationAdditional Disclosure
Additional Disclosure The Genetics of Prostate Cancer: Clinical Implications William J. Catalona, MD Collaborator with decode genetics, Inc. Non-paid consultant with no financial interest or support Northwestern
More informationPRENATAL TREATMENT AND FERTILITY OF FEMALE PATIENTS WITH CONGENITAL ADRENAL HYPERPLASIA
PRENATAL TREATMENT AND FERTILITY OF FEMALE PATIENTS WITH CONGENITAL ADRENAL HYPERPLASIA Nguyen Ngoc Khanh, Vu Chi Dung et al Vietnam Children s Hospital (VCH) Hanoi, Vietnam Outline Intruduction Prenatal
More informationGENETIC VARIATION AND PROSTATE CANCER
UMEÅ UNIVERSITY MEDICAL DISSERTATIONS New series No. 1114 ISSN 0346 6612 ISBN 978 91 7264 367 3 GENETIC VARIATION AND PROSTATE CANCER Population based association studies in Sweden SARA LINDSTRÖM Umeå
More informationReproductive DHEA Analyte Information
Reproductive DHEA Analyte Information - 1 - DHEA Introduction DHEA (dehydroepiandrosterone), together with other important steroid hormones such as testosterone, DHT (dihydrotestosterone) and androstenedione,
More informationIn situ androgen producing enzymes in human prostate cancer
Endocrine-Related Cancer (2005) 12 101 107 In situ androgen producing enzymes in human prostate cancer Yasuhiro Nakamura 1,2, Takashi Suzuki 1, Masao Nakabayashi 1, Mareyuki Endoh 1, Kazuhiro Sakamoto
More informationAssociation between the CYP11B2 gene 344T>C polymorphism and coronary artery disease: a meta-analysis
Association between the CYP11B2 gene 344T>C polymorphism and coronary artery disease: a meta-analysis Y. Liu, H.L. Liu, W. Han, S.J. Yu and J. Zhang Department of Cardiology, The General Hospital of the
More informationIVF Michigan, Rochester Hills, Michigan, and Reproductive Genetics Institute, Chicago, Illinois
FERTILITY AND STERILITY VOL. 80, NO. 4, OCTOBER 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. CASE REPORTS Preimplantation
More informationIntersex is a group of conditions where there is a discrepancy between the external genitals and the internal genitals (the testes and ovaries).
Intersex to use the sharing features on this page, please enable JavaScript. Share on facebookshare on IwitterBookmark & SharePrintcr-lnendly version Intersex is a group of conditions where
More informationPrevalent Mutations in Prostate Cancer
Journal of Cellular Biochemistry 97:433 447 (2006) PROSPECTS Prevalent Mutations in Prostate Cancer Jin-Tang Dong* Departments of Hematology and Oncology, and Urology, Winship Cancer Institute, Program
More informationInformation for You and Your Family
Information for You and Your Family What is Prevention? Cancer prevention is action taken to lower the chance of getting cancer. In 2017, more than 1.6 million people will be diagnosed with cancer in the
More informationNo cases of precocious puberty were reported during clinical trials of risperidone in, cases of precocious puberty have been
levels than adults. The growth hormone elevations reported for the 12 patients with growth hormone excess were modest and well below levels reported in children with gigantism. 7,8 None of the patients
More informationComputational Systems Biology: Biology X
Bud Mishra Room 1002, 715 Broadway, Courant Institute, NYU, New York, USA L#4:(October-0-4-2010) Cancer and Signals 1 2 1 2 Evidence in Favor Somatic mutations, Aneuploidy, Copy-number changes and LOH
More informationAsingle inherited mutant gene may be enough to
396 Cancer Inheritance STEVEN A. FRANK Asingle inherited mutant gene may be enough to cause a very high cancer risk. Single-mutation cases have provided much insight into the genetic basis of carcinogenesis,
More informationChemistry 107 Exam 4 Study Guide
Chemistry 107 Exam 4 Study Guide Chapter 10 10.1 Recognize that enzyme catalyze reactions by lowering activation energies. Know the definition of a catalyst. Differentiate between absolute, relative and
More informationHearing on SJR13 -- Proposes to amend the Nevada Constitution by repealing the limitation on the recognition of marriage.
Written statement of Lauren A. Scott- Executive Director Equality Nevada. 1350 Freeport Blvd, #107 Sparks, Nevada 89431 Testimony and Statement for the Record of Hearing on SJR13 -- Proposes to amend the
More informationAntibodies and T Cell Receptor Genetics Generation of Antigen Receptor Diversity
Antibodies and T Cell Receptor Genetics 2008 Peter Burrows 4-6529 peterb@uab.edu Generation of Antigen Receptor Diversity Survival requires B and T cell receptor diversity to respond to the diversity of
More informationMRC-Holland MLPA. Description version 08; 07 May 2015
mix P185-C1 Intersex Lot C1-0611: As compared to the previous version B2 (lot B2-0311), s for CYP21A2 have been removed and s for the CXorf21 gene as well as additional s for NR0B1, NR5A1 and the Y chromosome
More informationP R O S T A T E S U P P O R T :
P R O S T A T E S U P P O R T : GRAMINEX Flower Pollen Extract Alterations in the Intraprostatic Hormonal Metabolism by the Pollen Extract Cernilton N Sabine Tunn, M. Krieg Introduction A number of hypotheses
More informationMolecular Oncology, oncology parameters see each test
Molecular Oncology, oncology parameters see each test DPD deficiency Dihydropyrimidine dehydrogenase deficiency (DPD deficiency) is an autosomal recessive metabolic disorder in which there is absent or
More informationAssociation between ERCC1 and ERCC2 polymorphisms and breast cancer risk in a Chinese population
Association between ERCC1 and ERCC2 polymorphisms and breast cancer risk in a Chinese population R. Zhao and M.F. Ying Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University,
More information